Skip to main content

Day: March 22, 2021

InterDigital to Present at the Sidoti Virtual Investor Conference

WILMINGTON, Del., March 22, 2021 (GLOBE NEWSWIRE) — InterDigital, Inc. (NASDAQ:IDCC), a mobile and video technology research and development company, today announced that the company will be presenting at the Sidoti Virtual Investor Conference on Thursday, March 25, 2021 at 10:00 AM ET. The event will be webcast live and an archived replay of the presentation will also be available following the conferences. For more information, please visit the Investors section of the company’s website closer to the event. About InterDigital® InterDigital develops mobile and video technologies that are at the core of devices, networks, and services worldwide. We solve many of the industry’s most critical and complex technical challenges, inventing solutions for more efficient broadband networks, better video delivery, and richer multimedia experiences...

Continue reading

Saratoga Investment Corp. Increases Quarterly Dividend by $0.01 to $0.43 per Share for the Quarter Ended February 28, 2021

NEW YORK, March 22, 2021 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that its Board of Directors has declared a quarterly dividend of $0.43 per share for the fiscal quarter ended February 28, 2021, payable on April 22, 2021, to all stockholders of record at the close of business on April 8, 2021. This is an increase of $0.01 per share from last quarter.  “We are very pleased that our strong track record, healthy credit profile, robust deal pipeline, and ongoing asset growth continue to generate strong financial performance in support of a program of paying and increasing quarterly dividends,” said Christian L. Oberbeck, Chairman and Chief Executive Officer of Saratoga Investment. “Our dividend strategy is consistent with our overall...

Continue reading

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA and NEWTON, Mass., March 22, 2021 (GLOBE NEWSWIRE) — RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100™ (aviptadil) in advanced clinical development to treat severe COVID-19 patients, and Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the companies entered into a Collaboration and License Agreement (“CLA”) for worldwide development and commercialization of ACER-001. ACER-001...

Continue reading

Euro Manganese Announces Private Placement to Accelerate High-purity Manganese Development

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FORDISSEMINATION IN THE UNITED STATESAUD$30.0 million (CAD$29.0 Million) private placement oversubscribed, with strong institutional participation Proceeds of the Offering will be used to further advance Chvaletice Manganese Project, allowing completion of all site and technical work required for a final investment decision expected in 2022 Offering was anchored by a strategic investor and an ESG-focused fund, with strong support from several existing institutional shareholders Demand for high-purity manganese products continues to grow rapidly, bolstered by recent market developmentsVANCOUVER, British Columbia, March 22, 2021 (GLOBE NEWSWIRE) —  Euro Manganese Inc. (TSX-V / ASX: EMN) (the “Company” or “EMN“) is pleased to announce a private placement...

Continue reading

Saatchi Art Releases “New Voices” Campaign Featuring 100 Newly Discovered Emerging Artists

SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) — The world’s leading online art gallery for emerging artists, Saatchi Art, released its New Voices campaign featuring 100 emerging artists — a diverse group from a wide array of backgrounds and identities. This trailblazing group of artists represents a new generation of talent, each of whom is helping shift the conversation in the traditional art world by sharing often unheard perspectives and engaging in novel art-making approaches. New Voices celebrates Saatchi Art’s ongoing commitment to equity of representation in the arts with two-thirds of the artists featured self-identifying as BIPOC (Black, Indigenous and People of Color) and more than half identifying as women. As a pioneer in online art sales since 2010, Saatchi Art remains a trusted source in the emerging art market....

Continue reading

Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market

SEATTLE, March 22, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase agreement with institutional investors to purchase $50.0 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is $2.88. Under the terms of the securities purchase agreement, the Company has agreed to sell 17,361,100 shares of the Company’s common stock...

Continue reading

US Nuclear Completes $256,626 Shipment to China, Signs New Agreement With CNNC Subsidiary

LOS ANGELES, CA, March 22, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – US Nuclear Corp. (OTCQB: UCLE) recently completed a shipment to China of USN’S popular tritium and carbon-14 air samplers as well as portable tritium monitors worth a total of $256,626.   Furthermore, as part of US Nuclear’s expansion into the Chinese market, US Nuclear signed a new “Cooperation Agreement” on March 1, 2021 with Dalian Zhonghe Scientific and Technological Development Co., a subsidiary of China National Nuclear Corporation (CNNC). Together, the companies will work to design the perfect instrumentation to outfit Chinese nuclear power plants.  The instruments are planned to be built at a local factory in China to be cost-competitive and will be optimized for Chinese operators based on the local regulations and procedures.  This can be a game changer...

Continue reading

Clikia’s Maison Luxe Announces It Has Applied for a BitPay Account to Accept Bitcoin as an Additional Form of Payment for Purchases of Custom Luxury Goods to Increase Revenues

FORT LEE, NJ , March 22, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Clikia Corp. (OTC: CLKA) (“Clikia” or the “Company”), an emerging leader in the global high-end custom luxury goods marketplace, through its wholly owned subsidiary, Maison Luxe, is excited to announce that Maison Luxe intends to accept various forms of cryptocurrencies, including Bitcoin, as a form of payment to increase Revenues by offering additional forms of payment. The Company applied for a BitPay account and constructing its in-house cryptocurrency wallet. “In our view, cryptocurrencies are here to stay, and we are adjusting our protocols to allow for payments in major cryptocurrencies in the future,” noted Anil Idnani, CEO of Clikia and Founder of Maison Luxe. “This step prepares Maison Luxe for the future, where payment systems, currencies, and personal...

Continue reading

Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update

-Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market– -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved- CUPERTINO, Calif., March 22, 2021 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced its financial results for 2020 and provided a corporate update. “We are thrilled to enter this new year as a public company following the recent close of our merger in December. Following our listing on the NASDAQ Capital Market, we believe our interactions...

Continue reading

Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program

CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that its Board of Directors has authorized the repurchase of up to $40 million of shares of Catalyst’s outstanding common stock. “This share repurchase program reflects our confidence in the long-term outlook for the Company, including our ability to continue to generate strong cash flow,” said Patrick J. McEnany, the Company’s Chairman and Chief Executive Officer. “We believe that our strong balance sheet, earnings power and borrowing capability have us well-positioned to successfully...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.